ZA977510B - Stable non-hygroscopic crystalline form of N-[N-[N-(4-(piperidin-4-yl)butanoyl)-N-ethylglycyl]aspartyl]-L-Betacyclohexyl alanine amide, intermediates thereof, and preparation thereof and of antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides. - Google Patents
Stable non-hygroscopic crystalline form of N-[N-[N-(4-(piperidin-4-yl)butanoyl)-N-ethylglycyl]aspartyl]-L-Betacyclohexyl alanine amide, intermediates thereof, and preparation thereof and of antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides.Info
- Publication number
- ZA977510B ZA977510B ZA9707510A ZA977510A ZA977510B ZA 977510 B ZA977510 B ZA 977510B ZA 9707510 A ZA9707510 A ZA 9707510A ZA 977510 A ZA977510 A ZA 977510A ZA 977510 B ZA977510 B ZA 977510B
- Authority
- ZA
- South Africa
- Prior art keywords
- betacyclohexyl
- ethylglycyl
- pseudopeptides
- butanoyl
- aspartyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2428496P | 1996-08-21 | 1996-08-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA977510B true ZA977510B (en) | 1998-05-21 |
Family
ID=21819807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA9707510A ZA977510B (en) | 1996-08-21 | 1997-08-21 | Stable non-hygroscopic crystalline form of N-[N-[N-(4-(piperidin-4-yl)butanoyl)-N-ethylglycyl]aspartyl]-L-Betacyclohexyl alanine amide, intermediates thereof, and preparation thereof and of antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides. |
Country Status (20)
Country | Link |
---|---|
US (2) | US6153588A (no) |
EP (1) | EP0923553B1 (no) |
JP (1) | JP4008499B2 (no) |
KR (1) | KR20000068229A (no) |
CN (2) | CN1491942A (no) |
AP (1) | AP9901462A0 (no) |
AT (1) | ATE390438T1 (no) |
AU (1) | AU733591B2 (no) |
BG (1) | BG63538B1 (no) |
BR (1) | BR9711340A (no) |
CA (1) | CA2263647C (no) |
DE (1) | DE69738601T2 (no) |
EA (1) | EA001362B1 (no) |
IL (1) | IL128561A0 (no) |
NO (1) | NO990721L (no) |
OA (1) | OA10979A (no) |
PL (1) | PL331772A1 (no) |
SK (1) | SK21999A3 (no) |
WO (1) | WO1998007696A1 (no) |
ZA (1) | ZA977510B (no) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000068229A (ko) * | 1996-08-21 | 2000-11-25 | 오흘러 로스 제이. | 안정한 비-흡습성의 결정성 형태의 n-[n-n-(4-(피페리딘-4-일)부타노일)-n-에틸글리실] 화합물 |
WO1999019294A1 (en) * | 1997-05-14 | 1999-04-22 | Aventis Pharmaceuticals Products Inc. Legal/Patents | Process for the preparation of azacycloalkylalkanoyl pseudotetrapeptides |
AP1057A (en) * | 1997-10-10 | 2002-04-08 | Aventis Pharmaceuticals Products Inc | Process for the preparation of azacycloalkylalkanoyl pseudotetrapeptides. |
EP1155033A1 (en) * | 1998-12-30 | 2001-11-21 | Aventis Pharmaceuticals Products Inc. | Process for preparing a stable non-hygroscopic crystalline n-[n-[n-(piperdin-4-yl)butanoyl)-n-ethylglycyl]-(l)-aspartyl]-ss-cyclohexylalanine amide |
US20050238834A1 (en) * | 2004-04-21 | 2005-10-27 | Eastman Kodak Company | High modulus label with compliant carrier sheet |
WO2007024501A2 (en) | 2005-08-25 | 2007-03-01 | Medtronic Vascular, Inc. | Nitric oxide-releasing biodegradable polymers useful as medical devices and coatings therefore |
US8241619B2 (en) | 2006-05-15 | 2012-08-14 | Medtronic Vascular, Inc. | Hindered amine nitric oxide donating polymers for coating medical devices |
US7811600B2 (en) * | 2007-03-08 | 2010-10-12 | Medtronic Vascular, Inc. | Nitric oxide donating medical devices and methods of making same |
US8273828B2 (en) * | 2007-07-24 | 2012-09-25 | Medtronic Vascular, Inc. | Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation |
US20090222088A1 (en) * | 2008-02-29 | 2009-09-03 | Medtronic Vascular, Inc. | Secondary Amine Containing Nitric Oxide Releasing Polymer Composition |
US20090232863A1 (en) * | 2008-03-17 | 2009-09-17 | Medtronic Vascular, Inc. | Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers |
US20090232868A1 (en) * | 2008-03-17 | 2009-09-17 | Medtronic Vascular, Inc. | Nitric Oxide Releasing Polymer Composition |
US8158187B2 (en) * | 2008-12-19 | 2012-04-17 | Medtronic Vascular, Inc. | Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices |
US8709465B2 (en) * | 2009-04-13 | 2014-04-29 | Medtronic Vascular, Inc. | Diazeniumdiolated phosphorylcholine polymers for nitric oxide release |
US9704557B2 (en) * | 2013-09-25 | 2017-07-11 | Qualcomm Incorporated | Method and apparatus for storing retention time profile information based on retention time and temperature |
ES2924473T3 (es) | 2015-12-21 | 2022-10-07 | Univ Texas Tech System | Sistema y procedimiento de síntesis de péptidos GAP en fase de solución |
WO2019217116A1 (en) * | 2018-05-06 | 2019-11-14 | Gap Peptides Llc | Method for solution-phase peptide synthesis |
WO2020159837A1 (en) | 2019-02-01 | 2020-08-06 | Gap Peptides Llc | Synthesis strategy for gap protecting group |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4857508A (en) * | 1987-12-03 | 1989-08-15 | Monsanto Company | Novel platelet-aggregation inhibitor peptide derivatives |
US4992463A (en) * | 1988-07-20 | 1991-02-12 | Monsanto Company | Thienyl peptide mimetic compounds which are useful in inhibiting platelet aggregation |
US5332726A (en) * | 1989-09-29 | 1994-07-26 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Antithrombotic peptides and pseudopeptides |
US4952562A (en) * | 1989-09-29 | 1990-08-28 | Rorer Pharmaceutical Corporation | Anti-thrombotic peptides and pseudopeptides |
US5064814A (en) * | 1990-04-05 | 1991-11-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Anti-thrombotic peptide and pseudopeptide derivatives |
US5264420A (en) | 1990-09-27 | 1993-11-23 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
NZ239876A (en) * | 1990-09-27 | 1993-12-23 | Merck & Co Inc | Glycyl-b-alanine derivatives and pharmaceutical compositions thereof. |
US5218138A (en) | 1992-09-02 | 1993-06-08 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Stereoselective reduction of 3-hydroxyket-1-ones to 1,3-syn-dihydroxylated compounds |
US5340798A (en) * | 1992-10-14 | 1994-08-23 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
EP0706999A1 (en) * | 1993-06-30 | 1996-04-17 | Sumitomo Pharmaceuticals Company, Limited | Novel dipiperidine derivative |
US5780590A (en) * | 1993-10-15 | 1998-07-14 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides |
UA44258C2 (uk) * | 1993-10-15 | 2002-02-15 | Рон-Пуленк Рорер Фармасьютікалз Інк. | Антитромботичні азациклоалкілалканоілпептиди та псевдопептиди, фармацевтична композиція, що їх містить, спосіб профілактики або лікування тромбозу у ссавців (варіанти) |
KR100323274B1 (ko) | 1993-10-19 | 2002-12-16 | 스미또모 세이야꾸 가부시키가이샤 | 2,3-디아미노프로피온산유도체 |
KR20000068229A (ko) * | 1996-08-21 | 2000-11-25 | 오흘러 로스 제이. | 안정한 비-흡습성의 결정성 형태의 n-[n-n-(4-(피페리딘-4-일)부타노일)-n-에틸글리실] 화합물 |
AP1057A (en) * | 1997-10-10 | 2002-04-08 | Aventis Pharmaceuticals Products Inc | Process for the preparation of azacycloalkylalkanoyl pseudotetrapeptides. |
-
1997
- 1997-08-21 KR KR1019997001362A patent/KR20000068229A/ko not_active Application Discontinuation
- 1997-08-21 BR BR9711340A patent/BR9711340A/pt unknown
- 1997-08-21 IL IL12856197A patent/IL128561A0/xx unknown
- 1997-08-21 DE DE69738601T patent/DE69738601T2/de not_active Expired - Lifetime
- 1997-08-21 AU AU41563/97A patent/AU733591B2/en not_active Ceased
- 1997-08-21 SK SK219-99A patent/SK21999A3/sk unknown
- 1997-08-21 CA CA2263647A patent/CA2263647C/en not_active Expired - Fee Related
- 1997-08-21 EA EA199900217A patent/EA001362B1/ru not_active IP Right Cessation
- 1997-08-21 CN CNA021415722A patent/CN1491942A/zh active Pending
- 1997-08-21 WO PCT/US1997/014756 patent/WO1998007696A1/en not_active Application Discontinuation
- 1997-08-21 PL PL97331772A patent/PL331772A1/xx unknown
- 1997-08-21 JP JP51098398A patent/JP4008499B2/ja not_active Expired - Fee Related
- 1997-08-21 EP EP97939488A patent/EP0923553B1/en not_active Expired - Lifetime
- 1997-08-21 ZA ZA9707510A patent/ZA977510B/xx unknown
- 1997-08-21 AT AT97939488T patent/ATE390438T1/de not_active IP Right Cessation
- 1997-08-21 CN CN97198210A patent/CN1231659A/zh active Pending
- 1997-08-21 AP APAP/P/1999/001462A patent/AP9901462A0/en unknown
-
1999
- 1999-02-16 NO NO990721A patent/NO990721L/no unknown
- 1999-02-18 US US09/251,030 patent/US6153588A/en not_active Expired - Fee Related
- 1999-02-19 OA OA9900037A patent/OA10979A/en unknown
- 1999-03-04 BG BG103225A patent/BG63538B1/bg unknown
-
2000
- 2000-08-15 US US09/639,634 patent/US6753409B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
BG63538B1 (bg) | 2002-04-30 |
US6153588A (en) | 2000-11-28 |
JP4008499B2 (ja) | 2007-11-14 |
EP0923553A4 (en) | 1999-12-08 |
CA2263647A1 (en) | 1998-02-26 |
US6753409B1 (en) | 2004-06-22 |
AP9901462A0 (en) | 1999-03-31 |
JP2000517305A (ja) | 2000-12-26 |
AU733591B2 (en) | 2001-05-17 |
WO1998007696A1 (en) | 1998-02-26 |
CN1231659A (zh) | 1999-10-13 |
ATE390438T1 (de) | 2008-04-15 |
CA2263647C (en) | 2011-02-15 |
KR20000068229A (ko) | 2000-11-25 |
DE69738601T2 (de) | 2009-04-30 |
EA001362B1 (ru) | 2001-02-26 |
AU4156397A (en) | 1998-03-06 |
EP0923553B1 (en) | 2008-03-26 |
NO990721L (no) | 1999-04-20 |
BG103225A (en) | 2000-01-31 |
DE69738601D1 (de) | 2008-05-08 |
EP0923553A1 (en) | 1999-06-23 |
NO990721D0 (no) | 1999-02-16 |
CN1491942A (zh) | 2004-04-28 |
OA10979A (en) | 2001-11-01 |
SK21999A3 (en) | 2000-02-14 |
EA199900217A1 (ru) | 1999-08-26 |
IL128561A0 (en) | 2000-01-31 |
BR9711340A (pt) | 1999-08-17 |
PL331772A1 (en) | 1999-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA977510B (en) | Stable non-hygroscopic crystalline form of N-[N-[N-(4-(piperidin-4-yl)butanoyl)-N-ethylglycyl]aspartyl]-L-Betacyclohexyl alanine amide, intermediates thereof, and preparation thereof and of antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides. | |
PL334773A1 (en) | Endothelin antagonists: n-[[2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulphonyl]-4-(oxazoyl)[1,1'diphenyl]-ilyl-2]methyl]-n,3,3-trimethylabutane amide and n-(4,5-dimethyl-3-isoxazoyl)-2'-[3,3-dimethyl-2-oxo-1-pyrollydinyl)methyl]-4.-(2-oxazolyl)[1,1'-diphenyl]-2-sulphonamide and their salts | |
IL205233A0 (en) | A polypeptide comprising the amino acid sequence of osteoprotegerin from residues 22 to 401 inclusive, or a fragment or trunaction thereof | |
WO2001090138A3 (en) | SYNTHESIS OF N-[N-(3,3-DIMETHYLBUTYL)-L-α-ASPARTYL]-L-PHENYLALANINE 1-METHYL ESTER USING OXAZOLIDINONE DERIVATIVES | |
SG44989A1 (en) | Crystalline hydrochloride of (R)-(-)-2-{N-[4-(1,1-dioxid-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl}-chroman | |
IL129555A (en) | Pharmaceutical compositions containing n-(oxoacetyl)-amino acid amide derivatives for stimulating neurite growth | |
PL334184A1 (en) | Fungicidal compositions based on methyl n-(phenylacetyl)-n-(2,6-xylyl) alaninate | |
BR9806060B1 (pt) | composto n-[(aminoiminometil ou aminometil) fenil] propil amida, e, composição farmacêutica. | |
NZ501346A (en) | Valinyl aromatic beta amino acid dipeptide compounds having fungicidal activity and their agronomic use | |
HUP9900930A3 (en) | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides | |
AU1517895A (en) | N-(4-pyrimidinyl)amide pesticides | |
HUP0003847A3 (en) | Basic salts of n-[n-(3,3-dimethylbutyl)-l-alpha-aspartyl]-l-phenylalanine 1-methyl ester | |
GR3031637T3 (en) | Preparation containing a combination of 5-methylisoxazole-4-carboxylic acid-(4-trifluoromethyl)-anilide and n-(4-trifluoromethylphenyl)2-cyano-3-hydroxycrotonic acid amide | |
NO20001271D0 (no) | Søtningssalter av N-[N-(3,3-dimetylbutyl)-L-<alfa>-aspartyl]- L-fenylalanin-1-metylester | |
BG103197A (en) | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptiees | |
HUP0003573A3 (en) | Acid salts of n-[n-(3,3-dimethylbutyl)-l-alpha-aspartyl]-l-phenylalanine 1-methyl ester | |
PL339190A1 (en) | Complex compounds of metals with n-[n-(3,3-dimethylbutyl)-l-alpha-aspartil]-l-phenylamine 1-methyl ester | |
ZA976305B (en) | Liquid phase peptide syntheses of KL-4 pulmonary surfactant protein | |
AU1936499A (en) | Use of n-{n-(3,3-dimethylbutyl)-l-alpha-aspartyl}-l-phenylalanine 1-methyl esterin dairy and dairy analogue products | |
HUP0202516A3 (en) | Methods for crystallization of n-(1-(s)-ethoxycarbonyl-3-phenylpropyl)-l-alanine n-carboxyanhydride | |
WO2000052019A3 (en) | Crystallization products of neotame and methods for producing same | |
ZA958230B (en) | Compositions containing a P53 derived from protein or peptide an adjuvant and interleukin-12 and uses thereof | |
AU3735095A (en) | Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof | |
PL339360A1 (en) | Method of crystallising n-(1(s)-ethoxycarbonyl-3-phenylpropyl)-l-alanyl-l-proline maleate | |
FR2777279B1 (fr) | Nouvelles formes cristallines du 1s-[1alpha(2s*,3r*), 9 alpha] 6,10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl) -9[[(1-isoquinolyl)carbonyl]amino]octohydro-6h-pyridazino [1,2-a][1,2]diazepine-1-carboxamide |